151 related articles for article (PubMed ID: 22588067)
1. Podoplanin lymphatic density and invasion correlate with adverse clinicopathologic and biological factors and survival in neuroblastomas.
Ramani P; Somerville MS; May MT
Am J Surg Pathol; 2012 Jun; 36(6):908-15. PubMed ID: 22588067
[TBL] [Abstract][Full Text] [Related]
2. PROX1 lymphatic density correlates with adverse clinicopathological factors, lymph node metastases and survival in neuroblastomas.
Ramani P; Norton A; Somerville MS; May MT
J Neurooncol; 2012 Jul; 108(3):375-83. PubMed ID: 22382784
[TBL] [Abstract][Full Text] [Related]
3. LYVE-1 upregulation and lymphatic invasion correlate with adverse prognostic factors and lymph node metastasis in neuroblastoma.
Ramani P; Dungwa JV; May MT
Virchows Arch; 2012 Feb; 460(2):183-91. PubMed ID: 22241180
[TBL] [Abstract][Full Text] [Related]
4. VEGF-C, VEGF-D and VEGFR-3 expression in peripheral neuroblastic tumours.
Ramani P; Nash R; Radevsky L; Patel A; Luckett M; Rogers C
Histopathology; 2012 Dec; 61(6):1006-16. PubMed ID: 22804730
[TBL] [Abstract][Full Text] [Related]
5. Angiogenin up-regulation correlates with adverse clinicopathological and biological factors, increased microvascular density and poor patient outcome in neuroblastomas.
Dungwa JV; Uparkar U; May MT; Ramani P
Histopathology; 2012 May; 60(6):911-23. PubMed ID: 22372545
[TBL] [Abstract][Full Text] [Related]
6. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
7. High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas.
Ramani P; Nash R; Sowa-Avugrah E; Rogers C
J Neurooncol; 2015 Oct; 125(1):103-11. PubMed ID: 26318737
[TBL] [Abstract][Full Text] [Related]
8. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
9. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.
Tabyaoui I; Tahiri-Jouti N; Serhier Z; El Maani K; Cherkaoui S; Al Zemmouri M; Othmani MB; Zamiati S
Diagn Mol Pathol; 2013 Jun; 22(2):112-8. PubMed ID: 23628823
[TBL] [Abstract][Full Text] [Related]
10. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
Wang M; Zhou C; Cai R; Li Y; Gong L
Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
[TBL] [Abstract][Full Text] [Related]
11. GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours.
Ramani P; Headford A; May MT
Virchows Arch; 2013 Feb; 462(2):203-9. PubMed ID: 23307190
[TBL] [Abstract][Full Text] [Related]
12. [Pathology of peripheral neuroblastic tumors].
Wang L; He LJ; Shimada H
Zhonghua Bing Li Xue Za Zhi; 2012 Apr; 41(4):283-8. PubMed ID: 22800533
[No Abstract] [Full Text] [Related]
13. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
[TBL] [Abstract][Full Text] [Related]
14. MYCN gene amplification in patients with neuroblastic tumors.
Estiar MA; Fazilaty H; Aslanabadi S; Seifi M; Varghaei P; Rezamand A
Cell Mol Biol (Noisy-le-grand); 2014 Sep; 60(3):23-8. PubMed ID: 25231001
[TBL] [Abstract][Full Text] [Related]
15. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
16. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
17. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
[TBL] [Abstract][Full Text] [Related]
18. Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.
Koppen A; Ait-Aissa R; Koster J; Øra I; Bras J; van Sluis PG; Caron H; Versteeg R; Valentijn LJ
Int J Cancer; 2008 Apr; 122(7):1455-64. PubMed ID: 18059033
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic significance of MYCN amplification in children neuroblastic tumors].
Niu H; Xu T; Wang F; Chen Z; Gao Q; Yi P; Xia J
Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):111-7. PubMed ID: 25916642
[TBL] [Abstract][Full Text] [Related]
20. The neuroendocrine and neural profiles of neuroblastomas, ganglioneuroblastomas, and ganglioneuromas.
Molenaar WM; Baker DL; Pleasure D; Lee VM; Trojanowski JQ
Am J Pathol; 1990 Feb; 136(2):375-82. PubMed ID: 1689542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
